Antibody therapy reduces flare-ups in treatment-resistant COPD
Results come from two trials presented at European Respiratory Society International Congress Related items fromOnMedica Making sense of the new LABAs and LAMAs for COPD Physical activity decreases risk of dying in COPD End-of-life care in COPD Diagnosis of COPD needs to be improved CVD event risk raised soon after COPD exacerbations
An overview of glycopyrrolate/eFlow® CS in COPD. Expert Rev Respir Med. 2018 May 18;: Authors: Kerwin E, Ferguson GT Abstract INTRODUCTION: COPD is highly prevalent in the US and globally, requiring new treatment strategies due to the high disease burden and increase in the aging population. Here, we profile the newly FDA-approved LONHALA MAGNAIR (glycopyrrolate [GLY]/eFlow® Closed System [CS]; 25 mcg twice daily), a nebulized long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of COPD, including chronic bronchitis and/or emphysema. Areas covered: An overview of COP...
We read with interest the letter to the editor by Prof. Kawada, and appreciate the points that were raised. First, we agree that we did not adjust for severity of chronic obstructive pulmonary disease (COPD) in our analysis of administrative claims data.1 Inability to adjust for severity of disease is a known limitation of such administrative claims analysis.2 However, it is for that reason that we adjusted for concomitant medications and propensity scores — which, although it is not the same as severity assessment using spirometry or imaging — offers a means to account for severity of COPD.
I read the article by Vasquez et al1 with interest. The prevalences of noninvasive positive pressure ventilation, bilevel positive airway pressure, and continuous positive airway pressure in patients with chronic obstructive pulmonary disease were
Low physical activity (PA) is associated with adverse health outcomes independent of airflow limitation in COPD. Self-reported assessments are often limited to global estimates of PA and may not be directly translatable to patients' goals and motivations. We developed a task-oriented PA checklist and examined its performance relative to pedometer-assessed daily step count in two COPD cohorts.
Conclusions: Procaterol assist use modestly but significantly improved pulmonary function determined by spirometry and respiratory mechanics in patients with stable COPD treated with long-acting bronchodilators. Thus, inhaled procaterol has potential for assist use for COPD.
Conclusion Theophylline clearance was significantly associated with FFM and CYP1A2*1B genotypes in Chinese adult patients.
IJERPH, Vol. 15, Pages 1021: Analysis of Short-Term Smoking Effects in PBMC of Healthy Subjects—Preliminary Study International Journal of Environmental Research and Public Health doi: 10.3390/ijerph15051021 Authors: Joanna Wieczfinska Tomasz Kowalczyk Przemyslaw Sitarek Ewa Skała Rafal Pawliczak Early structural changes exist in the small airways before the establishment of Chronic Obstructive Pulmonary Disease (COPD). These changes are believed to be induced by oxidation. The aim of this study was to analyze the influence of short-term smoking on the expression of the genes contributing to airway r...
We examined questions using the National Health and Nutrition Examination Survey III database linked to the National Death Index. The data from 4434 participants were stratified into 4 groups, those with asthma, COPD, ACO, and those without any obstructive lung disease. We examined baseline demographics and used multivariate logistic regression to model the impact of demographics, smoking, and self-reported, physician-diagnosed lung disease on mortality generating odds ratios (ORs) and confidence intervals (CIs). RESULTS: Among 4434 participants, 120 (2.7%), 340 (7.6%), and 126 (2.8%) participants self-reported diagnos...
Acta Ophthalmologica, EarlyView.
International Journal of Nursing Practice, EarlyView.